• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NovaBridge Biosciences

    1/6/26 7:00:13 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBP alert in real time by email
    6-K 1 giva_pr_and_ir_deck_-_01.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

    For the month of January 2026

     

     

    Commission File Number: 001-39173

     

     

    NovaBridge Biosciences

    2440 Research Boulevard, Suite 400

    Rockville, MD 20850

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒                Form 40-F ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

    On January 6, 2026, NovaBridge Biosciences issued a press release and an investor presentation, copies of which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.

     


    EXHIBIT INDEX

     

    Exhibit No.

    Description

     

     

    99.1

    Press Release - NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

     

     

    99.2

    Investor Presentation - January 6, 2026

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    NovaBridge Biosciences

     

     

     

    By

    :

    /s/ Xi-Yong Fu

     

    Name

    :

    Xi-Yong (Sean) Fu

     

    Title

    :

    Chief Executive Officer

     

    Date: January 6, 2026


    Get the next $NBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBP

    DatePrice TargetRatingAnalyst
    2/6/2026$7.00 → $9.00Buy
    H.C. Wainwright
    More analyst ratings

    $NBP
    SEC Filings

    View All

    SEC Form 6-K filed by NovaBridge Biosciences

    6-K - NovaBridge Biosciences (0001778016) (Filer)

    1/22/26 4:05:02 PM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NovaBridge Biosciences

    6-K - NovaBridge Biosciences (0001778016) (Filer)

    1/22/26 7:00:01 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NovaBridge Biosciences

    6-K - NovaBridge Biosciences (0001778016) (Filer)

    1/16/26 4:05:03 PM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on NovaBridge Biosciences with a new price target

    H.C. Wainwright resumed coverage of NovaBridge Biosciences with a rating of Buy and set a new price target of $9.00 from $7.00 previously

    2/6/26 6:51:12 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

    ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company's ADSs in open market transactions. The purchases started on January 15, 2026 and are ongoing as of the date of this press release. As the planned purchases are to be executed by Fu Wei via his controlled entity, NovaBridge cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market. "2025 was a defining yea

    1/20/26 7:00:00 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

    Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-fits-all" treatments, as investors rotate capital into modular systems designed to hunt multiple cancer targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ:GTBP), ImmunityBio (NA

    1/16/26 8:00:00 AM ET
    $CHRS
    $ERAS
    $GTBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

    Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levelsThe median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohortsCombination was well tolerated; safety is comparable to the current standard of care treatmentData demonstrate that givastomig is a potential best-in-class C

    1/6/26 7:00:00 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBP
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

    Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levelsThe median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohortsCombination was well tolerated; safety is comparable to the current standard of care treatmentData demonstrate that givastomig is a potential best-in-class C

    1/6/26 7:00:00 AM ET
    $NBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations